Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Debt (2020 - 2022)

Historic Total Debt for Mereo BioPharma (MREO) over the last 3 years, with Q4 2022 value amounting to $486000.0.

  • Mereo BioPharma's Total Debt fell 9749.35% to $486000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $486000.0, marking a year-over-year decrease of 9749.35%. This contributed to the annual value of $19.4 million for FY2021, which is 645.92% down from last year.
  • Mereo BioPharma's Total Debt amounted to $486000.0 in Q4 2022, which was down 9749.35% from $20.1 million recorded in Q2 2022.
  • In the past 5 years, Mereo BioPharma's Total Debt registered a high of $25.1 million during Q2 2021, and its lowest value of $486000.0 during Q4 2022.
  • In the last 3 years, Mereo BioPharma's Total Debt had a median value of $19.7 million in 2021 and averaged $17.4 million.
  • Its Total Debt has fluctuated over the past 5 years, first surged by 3915.95% in 2021, then tumbled by 9749.35% in 2022.
  • Quarter analysis of 3 years shows Mereo BioPharma's Total Debt stood at $21.3 million in 2020, then fell by 9.03% to $19.4 million in 2021, then crashed by 97.49% to $486000.0 in 2022.
  • Its Total Debt was $486000.0 in Q4 2022, compared to $20.1 million in Q2 2022 and $19.4 million in Q4 2021.